Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01964014
Other study ID # MED-CT4-11-391
Secondary ID
Status Completed
Phase Phase 4
First received October 1, 2013
Last updated July 19, 2016
Start date October 2013
Est. completion date October 2015

Study information

Verified date July 2016
Source Ajou University School of Medicine
Contact n/a
Is FDA regulated No
Health authority Korea: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The objective of this study is to assess the efficacy and safety and Immunosuppressant Therapy Barrier Scale (ITBS) of once daily immunosuppressant maintenance therapy in patients who had kidney transplantations earlier.


Description:

This is a 6-month, single-arm, multi-center, open-label, continuous cohort study. 160 subjects who had kidney transplantations at least 3 months earlier will participate in the study. All enrolled subjects will discontinue the existing Tacrolimus preparations for 6 months from enrollment and be converted to Extended Release Tacrolimus at a biologically equivalent dose. They will also discontinue enteric-coated mycophenolate sdium or mycophenolate sodium and be treated with Sirolimus and observed.


Recruitment information / eligibility

Status Completed
Enrollment 160
Est. completion date October 2015
Est. primary completion date October 2015
Accepts healthy volunteers No
Gender Both
Age group 20 Years to 65 Years
Eligibility Inclusion Criteria:

- Men or women at the age of 20 to 65 who had kidney transplantations at least 3 months ago.

- Recipients of kidney transplantations from a deceased / cadaveric donor, non-heart beating cadaveric donor / organ donor after cardiac death, or non-blood related or blood related live donor.

- Patients being treated with Tacrolimus or Extended Release Tacrolimus as the existing immunosuppressant maintenance therapy.

- Able and willing to give informed consent to study participation, having signed the informed consent form according to appropriate procedures, and capable of participating in the study by making visits according to study plans.

Exclusion Criteria:

- HIV, HBsAg, or anti-HCV test positive patients or having received kidney transplantations from an HIV, HBsAg, or anti-HCV test positive donor.

- History of severe allergies or hypersensitivities to drugs used in the study or other drugs with a similar chemical structure requiring acute (within the past 4 weeks) or chronic treatment.

- Having received other investigational product within 30 days prior to enrollment into this study.

- Women of childbearing potential who plan to become pregnant, pregnant and/or lactating women, women who do not intend to use effective contraceptives.

- Having uncontrolled diseases or medical conditions requiring continuous treatment.

- History of alcohol or drug addiction within the past 3 months or incapable of appropriate communications due to reasons such as mental illness.

- Absolute neutrophil count <1,500/mm3 or leukocyte count <2,500/mm3 or platelet count <75,000/mm3 at screening or severe metabolic disorders (including functional disorders).

- Having experienced the following condition within the past 1 month:

- Serum creatinine > 2.0 mg/dl more than twice.

- 24 hr urine protein=750 mg/day

- Diagnosed with or treated for a rejection reaction or an infection or hospitalized due to other medical reasons.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
advagrf
All enrolled subjects will discontinue the existing Tacrolimus preparations for 6 months from enrollment and be converted to Extended Release Tacrolimus at a biologically equivalent dose. They will also discontinue enteric-coated mycophenolate sdium or mycophenolate sodium and be treated with Sirolimus and observed. advagrf+sirolimus one time to eat.

Locations

Country Name City State
Korea, Republic of Nephrology, Pusan National University Hospital Busan
Korea, Republic of Bundang CHA Medical Center, Gyeonggi-do
Korea, Republic of Inje University Ilsan Paik Hospital Gyeonggido
Korea, Republic of Korea University Medical Center Seoul
Korea, Republic of Severance Hospital Seoul
Korea, Republic of Soonchunhyang University Hosptial Seoul
Korea, Republic of Dept. of Surgery, Ulsan University Hospital Ulsan

Sponsors (1)

Lead Sponsor Collaborator
Ajou University School of Medicine

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary acute rejection reaction treated or confirmed by biopsy, loss of graft, death, or lost to follow-up The primary objective of this study is to investigate the efficacy of Advagraf ® (Extended Release Tacrolimus) at 6 months after immunosuppressant conversion to the once daily therapy. The efficacy is defined as the incidence rate of composite endpoints of efficacy failure (acute rejection reaction treated or confirmed by biopsy, loss of graft, death, or lost to follow-up). 6months No
Secondary renal functions Difference in renal functions (eGFR by MDRD method), urine protein excretion and P/C ratio (A/C ratio), transplant kidney biopsy histology (if biopsy is performed). 6months No
Secondary serious adverse events Frequency and severity of adverse events and serious adverse events 6months No
Secondary cardiovascular health Treatment impact on cardiovascular health: blood pressure and cardiovascular events (acute myocardial infarction, unstable angina pectoris, heart failure, stroke). 6months No
Secondary NODAT Incidence rate of new onset diabetes after transplantation (NODAT) requiring treatment. 6months No
Secondary hematology issue Frequency of anemia, leucopenia, and thrombocytopenia. 6months No
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT01155128 - Effects of an Exercise Program in Patients With Hypertensive Chronic Kidney Disease Phase 4
Completed NCT00962000 - Study of How the Dose of Dialysis is Affected by Dialysate Flow Rate N/A
Completed NCT00560014 - Nutrient Levels Alter Transplant Outcome N/A
Completed NCT03274921 - Biomarkers of Cardiovascular Complications in Chronic Kidney Disease
Recruiting NCT01728415 - Effects of High-intensity Interval Training in Patients in Hemodialysis N/A
Completed NCT01532297 - Application of Citrate Dialysate in Chronic Haemodialysis N/A
Completed NCT04100551 - Relationship Between Chronic Renal Disease and Risk Stratification for Chronic Ulcer on the on the Diabetic Foot
Recruiting NCT04428827 - Outcome of Patients With Primary Aldosteronism
Completed NCT02299661 - Pilot PK/PD Study of DS-1093a in Patients With Chronic Kidney Disease Phase 1
Recruiting NCT02190318 - Residual Renal Function Preservation in Peritoneal Dialysis Patients N/A
Terminated NCT01402219 - Nephrotoxicity of Iopamidol Versus Iodixanol in High-Risk Patients Phase 4
Not yet recruiting NCT04157647 - Hemadsorption During and After Cardiopulmonary Bypass to Modulate the Inflammatory Response N/A
Completed NCT04897672 - 2D-speckle Tracking in Pediatric Renal Chronic Disease
Terminated NCT02375711 - Immunosenescence and Hepatitis B Virus (HBV) Vaccine Efficacy in Chronic Renal Disease Patient N/A
Not yet recruiting NCT04940819 - A Mobile Application Based Dietary Self Management Intervention in Chinese Chronic Kidney Disease Patients N/A
Completed NCT01817322 - Kidney Graft Function Under the Immunosuppression Strategies Phase 4
Completed NCT05383261 - The Impact of the Social Factors and Rehabilitation Program to Address the Implications on Kidney Failure in Hail
Not yet recruiting NCT06439862 - Study of the Quality of Life in School Aged-children With Posterior Urethral Valves
Completed NCT02834026 - Impact of the Cycle Ergometer in Muscle Strength and Pulmonary Function in Patients in Hemodialysis N/A
Completed NCT02072837 - Dyslipidemia-related Risk Factors in Dialysis N/A